Optimization of secukinumab dose regimens in patients with moderate-to-severe plaque psoriasis via exposure-response modeling

References

• Damiani G, Bragazzi NL, Karimkhani Aksut C, et al. The global, regional, and national burden of psoriasis: results and insights from the global burden of disease 2019 study. Front Med. 2021;8. doi: 10.3389/fmed.2021.743180
   Web of Science ®Google Scholar
• Boehncke WH, Schön MP. Psoriasis. Lancet. 2015;386(9997):983–994. doi: 10.1016/S0140-6736(14)61909-7
   PubMed Web of Science ®Google Scholar
• Damiani G, Cazzaniga S, Conic RRZ, et al. Pruritus characteristics in a large Italian cohort of psoriatic patients. J Eur Acad Dermatol Venereol. 2019;33(7):1316–1324. doi: 10.1111/jdv.15539
   PubMed Web of Science ®Google Scholar
• Menter A, Strober BE, Kaplan DH, et al. Joint AAD-NPF guidelines of care for the management and treatment of psoriasis with biologics. J Am Acad Dermatol. 2019;80(4):1029–1072. doi: 10.1016/j.jaad.2018.11.057
   PubMed Web of Science ®Google Scholar
• Armstrong AW, Read RC. Pathophysiology, clinical presentation, and treatment of psoriasis. JAMA. 2020;323(19):1945. doi: 10.1001/jama.2020.4006
   PubMed Web of Science ®Google Scholar
• Takeshita J, Grewal S, Langan SM, et al. Psoriasis and comorbid diseases: epidemiology. J Am Acad Dermatol. 2017;76(3):377–390. doi: 10.1016/j.jaad.2016.07.064
   PubMed Web of Science ®Google Scholar
• Menter A, Korman NJ, Elmets CA, et al. Guidelines of care for the management of psoriasis and psoriatic arthritis. J Am Acad Dermatol. 2011;65(1):137–174. doi: 10.1016/j.jaad.2010.11.055
   PubMed Web of Science ®Google Scholar
• Amin M, No DJ, Egeberg A, et al. Choosing first-line biologic treatment for moderate-to-severe psoriasis: what does the evidence say? Am J Clin Dermatol. 2017;19(1):1–13. doi: 10.1007/s40257-017-0328-3
   Web of Science ®Google Scholar
• Armstrong AW, Puig L, Joshi A, et al. Comparison of biologics and oral treatments for plaque psoriasis. JAMA Dermatol. 2020;156(3):258. doi: 10.1001/jamadermatol.2019.4029
   PubMed Web of Science ®Google Scholar
• Ruggiero A, Picone V, Martora F, et al. Guselkumab, Risankizumab, and tildrakizumab in the management of psoriasis: a review of the real-world evidence. Clin Cosmet Investig Dermatol. 2022;15:1649–1658. doi: 10.2147/CCID.S364640
   PubMed Web of Science ®Google Scholar
• Blauvelt A, Papp KA, Griffiths CEM, et al. Efficacy and safety of guselkumab, an anti-interleukin-23 monoclonal antibody, compared with adalimumab for the continuous treatment of patients with moderate to severe psoriasis: results from the phase III, double-blinded, placebo- and active comparator-controlled VOYAGE 1 trial. J Am Acad Dermatol. 2017;76(3):405–417. doi: 10.1016/j.jaad.2016.11.041
   PubMed Web of Science ®Google Scholar
• Marasca C, Fornaro L, Martora F, et al. Onset of vitiligo in a psoriasis patient on ixekizumab. Dermatol Ther. 2021;34(5): doi: 10.1111/dth.15102
   Web of Science ®Google Scholar
• Garnock-Jones KP. Secukinumab: a review in moderate to severe plaque psoriasis. Am J Clin Dermatol. 2015;16(4):323–330. doi: 10.1007/s40257-015-0143-7
   PubMed Web of Science ®Google Scholar
• U.S. prescribing information for COSENTYX® (secukinumab). U.S. Food and drug administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2021/125504_S050_S051lbl.pdf [Last accessed 13 Oct 2022].
   Google Scholar
• Lee JE, Wang J, Florian J, et al. Effect of body weight on risk-benefit and dosage regimen recommendation of secukinumab for the treatment of moderate to severe plaque psoriasis. Clin Pharmacol Ther. 2019;106(1):78–80. doi: 10.1002/cpt.1478
   PubMed Web of Science ®Google Scholar
• Phung M, Ighani A, Georgakopoulos JR, et al. Off-label high-dose secukinumab for the treatment of moderate-to-severe psoriasis. J Cutan Med Surg. 2019;23(4):391–393. doi: 10.1177/1203475419843118
   PubMed Web of Science ®Google Scholar
• Beecker J, Joo J. Treatment of moderate to severe psoriasis with high-dose (450-mg) secukinumab: case reports of off-label use. J Cutan Med Surg. 2017;22(1):86–88. doi: 10.1177/1203475417721424
   PubMed Web of Science ®Google Scholar
• Augustin M, Reich K, Yamauchi P, et al. Secukinumab dosing every 2 weeks demonstrated superior efficacy compared with dosing every 4 weeks in patients with psoriasis weighing 90 kg or more: results of a randomized controlled trial. Br J Dermatol. 2022;186(6):942–954. doi: 10.1111/bjd.20971
   PubMed Web of Science ®Google Scholar
• Reich K, Puig L, Szepietowski JC, et al. Secukinumab dosing optimization in patients with moderate‐to‐severe plaque psoriasis: results from the randomized, open‐label OPTIMISE study. Br J Dermatol. 2019;182(2):304–315. doi: 10.1111/bjd.18143
   PubMed Web of Science ®Google Scholar
• Purmonen T, Puolakka K, Mishra D, et al. Cost-effectiveness of secukinumab compared to other biologics in the treatment of ankylosing spondylitis in Finland. Clinicoecon Outcomes Res 2019; 11: 159–168. doi: 10.2147/CEOR.S192235
   PubMed Web of Science ®Google Scholar
• Brezinski EA, Dhillon JS, Armstrong AW. Economic burden of psoriasis in the United States. JAMA Dermatol. 2015;151(6):651. doi: 10.1001/jamadermatol.2014.3593
   PubMed Web of Science ®Google Scholar
• Bruin G, Loesche C, Nyirady J, et al. Population pharmacokinetic modeling of secukinumab in patients with moderate to severe psoriasis. J Clin Pharmacol. 2017;57(7):876–885. doi: 10.1002/jcph.876
   PubMed Web of Science ®Google Scholar
• Clinical pharmacology and biopharmaceutics review (s) for COSENTYX® (secukinumab). U.S. Food and drug administration. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2015/125504Orig1s000ClinPharmR.pdf [Last accessed 13 Oct 2022].
   Google Scholar
• Hooker AC, Staatz CE, Karlsson MO. Conditional weighted residuals (CWRES): a model diagnostic for the FOCE method. Pharm Res. 2007;24(12):2187–2197. doi: 10.1007/s11095-007-9361-x
   PubMed Web of Science ®Google Scholar
• Ette EI. Stability and performance of a population pharmacokinetic model. J Clin Pharmacol. 1997;37(6):486–495. doi: 10.1002/j.1552-4604.1997.tb04326.x
   PubMed Web of Science ®Google Scholar
• Thai HT, Mentré F, Holford NHG, et al. Evaluation of bootstrap methods for estimating uncertainty of parameters in nonlinear mixed-effects models: a simulation study in population pharmacokinetics. J Pharmacokinet Pharmacodyn. 2013;41(1):15–33. doi: 10.1007/s10928-013-9343-z
   PubMed Web of Science ®Google Scholar
• Wang DD, Zhang S. Standardized visual predictive check versus visual predictive check for model evaluation. J Clin Pharmacol. 2012;52(1):39–54. doi: 10.1177/0091270010390040
   PubMed Web of Science ®Google Scholar
• Chow SC. Bioavailability and bioequivalence in drug development. Wiley Interdiscip Rev Comput Stat. 2014;6(4):304–312. doi: 10.1002/wics.1310
   PubMedGoogle Scholar
• Martora F, Megna M, Battista T, et al. Adalimumab, Ustekinumab, and secukinumab in the management of Hidradenitis Suppurativa: a review of the real-life experience. Clin Cosmet Investig Dermatol. 2023;16:135–148. doi: 10.2147/CCID.S391356
   PubMed Web of Science ®Google Scholar
• Kimball AB, Jemec GBE, Alavi A, et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet. 2023;401:747–761. doi: 10.1016/S0140-6736(23)00022-3
   PubMed Web of Science ®Google Scholar
• Novel drug approvals for 2015. U.S. Food and Drug Administration. Available at: https://www.fda.gov/drugs/new-drugs-fda-cders-new-molecular-entities-and-new-therapeutic-biological-products/novel-drug-approvals-2015 [Last accessed 13 Oct 2022].
   Google Scholar
• Human medicine European public assessment report: Cosentyx® (secukinu-mab). European Medicines Agency. Available at: https://www.ema.europa.eu/en/medicines/human/EPAR/cosentyx [Last accessed 13 Oct 2022].
   Google Scholar
• Boucher M, Bennetts M. The many flavors of model-based meta-analysis: part I-Introduction and landmark data. CPT Pharmacometrics Syst Pharmacol. 2016;5(2):54–64. doi: 10.1002/psp4.12041
   PubMedGoogle Scholar
• Boucher M, Bennetts M. Many flavors of model-based meta-analysis: part II - Modeling summary level longitudinal responses. CPT Pharmacometrics Syst Pharmacol. 2018;7(5):288–297. doi: 10.1002/psp4.12299
   PubMedGoogle Scholar
• Reich K, Körber A, Mrowietz U, et al. Secukinumab 2‐weekly vs. 4‐weekly dosing in patients with plaque‐type psoriasis: results from the randomized GAIN study. Br J Dermatol. 2020;184(5):849–856. doi: 10.1111/bjd.19398
   PubMed Web of Science ®Google Scholar
• Damiani G, Odorici G, Pacifico A, et al. Secukinumab loss of efficacy is perfectly counteracted by the Introduction of combination therapy (rescue therapy): data from a multicenter real-life study in a cohort of Italian psoriatic patients that avoided secukinumab switching. Pharmaceuticals (Basel). 2022;15(1):95. doi: 10.3390/ph15010095
   PubMedGoogle Scholar
• Damiani G, Conic RRZ, Pigatto PDM, et al. Predicting secukinumab fast-responder profile in psoriatic patients Advanced Application Of Artificial-Neural-Networks(ANNs). J Drugs Dermatol. 2020;19(12):1241–1246. doi: 10.36849/JDD.2020.5006
   PubMed Web of Science ®Google Scholar